{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:58Z","timestamp":1792184698413,"version":"4.4.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of bone-rebuilding anabolic agents for potential use in the treatment of bone loss conditions, such as osteoporosis, has been a long-standing goal. Genetic studies in humans and mice have shown that the secreted protein sclerostin is a key negative regulator of bone formation, although the magnitude and extent of sclerostin's role in the control of bone formation in the aging skeleton is still unclear. To study this unexplored area of sclerostin biology and to assess the pharmacologic effects of sclerostin inhibition, we used a cell culture model of bone formation to identify a sclerostin neutralizing monoclonal antibody (Scl-AbII) for testing in an aged ovariectomized rat model of postmenopausal osteoporosis. Six-month-old female rats were ovariectomized and left untreated for 1 yr to allow for significant estrogen deficiency-induced bone loss, at which point Scl-AbII was administered for 5 wk. Scl-AbII treatment in these animals had robust anabolic effects, with marked increases in bone formation on trabecular, periosteal, endocortical, and intracortical surfaces. This not only resulted in complete reversal, at several skeletal sites, of the 1 yr of estrogen deficiency-induced bone loss, but also further increased bone mass and bone strength to levels greater than those found in non-ovariectomized control rats. Taken together, these preclinical results establish sclerostin's role as a pivotal negative regulator of bone formation in the aging skeleton and, furthermore, suggest that antibody-mediated inhibition of sclerostin represents a promising new therapeutic approach for the anabolic treatment of bone-related disorders, such as postmenopausal osteoporosis.<\/jats:p>","DOI":"10.1359\/jbmr.081206","type":"journal-article","created":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T12:32:07Z","timestamp":1228221127000},"page":"578-588","source":"Crossref","is-referenced-by-count":667,"title":["Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis"],"prefix":"10.1093","volume":"24","author":[{"given":"Xiaodong","family":"Li","sequence":"first","affiliation":[{"name":"These authors contributed equally to this work"},{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Ominsky","sequence":"additional","affiliation":[{"name":"These authors contributed equally to this work"},{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S","family":"Warmington","sequence":"additional","affiliation":[{"name":"These authors contributed equally to this work"},{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Morony","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Shalhoub","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tipton","sequence":"additional","affiliation":[{"name":"Department of Protein Sciences, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Haldankar","sequence":"additional","affiliation":[{"name":"Department of Protein Sciences, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Protein Sciences, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Winters","sequence":"additional","affiliation":[{"name":"Department of Protein Sciences, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Boone","sequence":"additional","affiliation":[{"name":"Department of Protein Sciences, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaopo","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Tian","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua Zhu","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Kostenuik","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Scott","family":"Simonet","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Lacey","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Paszty","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020320032289700_bib1","first-page":"68","author":"Stepnick","year":"2004"},{"key":"2024020320032289700_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/jc.2007-0042","article-title":"Update in osteoporosis and metabolic bone disorders","volume":"92","author":"Shoback","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320032289700_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/jmg.25.3.200","article-title":"Sclerosteosis","volume":"25","author":"Beighton","year":"1988","journal-title":"J Med Genet"},{"key":"2024020320032289700_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","article-title":"The natural history of sclerosteosis","volume":"63","author":"Hamersma","year":"2003","journal-title":"Clin Genet"},{"key":"2024020320032289700_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2024020320032289700_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet"},{"key":"2024020320032289700_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.33.3.267","article-title":"Sclerosteosis: Neurogenetic and pathophysiologic analysis of an American kinship","volume":"33","author":"Stein","year":"1983","journal-title":"Neurology"},{"key":"2024020320032289700_bib8","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"2024020320032289700_bib9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med"},{"key":"2024020320032289700_bib10","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"key":"2024020320032289700_bib11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength*","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320032289700_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0169-6009(91)90124-I","article-title":"The ovariectomized rat model of postmenopausal bone loss","volume":"15","author":"Kalu","year":"1991","journal-title":"Bone Miner"},{"key":"2024020320032289700_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0169-6009(92)90809-R","article-title":"On the rat model of human osteopenias and osteoporoses","volume":"18","author":"Frost","year":"1992","journal-title":"Bone Miner"},{"key":"2024020320032289700_bib14","volume-title":"Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis","author":"Office of Freedom of Information","year":"1994"},{"key":"2024020320032289700_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1172\/JCI116985","article-title":"Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats","volume":"93","author":"Black","year":"1994","journal-title":"J Clin Invest"},{"key":"2024020320032289700_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/jbmr.5650090517","article-title":"Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats","volume":"9","author":"Sato","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020320032289700_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0022-3565(25)20968-5","article-title":"Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats","volume":"279","author":"Sato","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"2024020320032289700_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1359\/jbmr.071207","article-title":"Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat","volume":"23","author":"Gasser","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320032289700_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00223-007-9084-3","article-title":"Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography","volume":"82","author":"Brouwers","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"2024020320032289700_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1359\/jbmr.1998.13.6.1005","article-title":"The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats","volume":"13","author":"Li","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020320032289700_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/8756-3282(94)00033-V","article-title":"The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in a sexually mature, ovariectomized rat model","volume":"16","author":"Mosekilde","year":"1995","journal-title":"Bone"},{"key":"2024020320032289700_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/8756-3282(95)00115-T","article-title":"Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats","volume":"16","author":"Li","year":"1995","journal-title":"Bone"},{"key":"2024020320032289700_bib23","doi-asserted-by":"crossref","first-page":"19992","DOI":"10.1074\/jbc.M001758200","article-title":"Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes","volume":"275","author":"Smith","year":"2000","journal-title":"J Biol Chem"},{"key":"2024020320032289700_bib24","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","article-title":"OPG and PTH-(1\u201334) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats","volume":"142","author":"Kostenuik","year":"2001","journal-title":"Endocrinology"},{"key":"2024020320032289700_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024020320032289700_bib26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jor.1100080418","article-title":"Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats","volume":"8","author":"Turner","year":"1990","journal-title":"J Orthop Res"},{"key":"2024020320032289700_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1083\/jcb.96.1.191","article-title":"In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria","volume":"96","author":"Sudo","year":"1983","journal-title":"J Cell Biol"},{"key":"2024020320032289700_bib28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00003086-199210000-00025","article-title":"Osteon morphometry in females with femoral neck fractures","volume":"283","author":"Barth","year":"1992","journal-title":"Clin Orthop Relat Res"},{"key":"2024020320032289700_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(98)00143-4","article-title":"Regional differences in cortical porosity in the fractured femoral neck","volume":"24","author":"Bell","year":"1999","journal-title":"Bone"},{"key":"2024020320032289700_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S8756-3282(02)00779-2","article-title":"Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro","volume":"31","author":"Wachter","year":"2002","journal-title":"Bone"},{"key":"2024020320032289700_bib31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1359\/jbmr.071108","article-title":"Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women","volume":"23","author":"Boutroy","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320032289700_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1115\/1.2891234","article-title":"Candidates for the mechanosensory system in bone","volume":"113","author":"Cowin","year":"1991","journal-title":"J Biomech Eng"},{"issue":"Suppl 1","key":"2024020320032289700_bib33","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1007\/BF01673415","article-title":"Osteocytes, strain detection, bone modeling and remodeling","volume":"53","author":"Lanyon","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2024020320032289700_bib34","first-page":"25","article-title":"The structure of bone tissues and the cellular control of their deposition","volume":"101","author":"Marotti","year":"1996","journal-title":"Ital J Anat Embryol"},{"key":"2024020320032289700_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(99)00241-0","article-title":"Toward a unifying theory of bone remodeling","volume":"26","author":"Martin","year":"2000","journal-title":"Bone"},{"key":"2024020320032289700_bib36","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"key":"2024020320032289700_bib37","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Semenov","year":"2005","journal-title":"J Biol Chem"},{"key":"2024020320032289700_bib38","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"2024020320032289700_bib39","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024020320032289700_bib40","doi-asserted-by":"crossref","first-page":"38276","DOI":"10.1074\/jbc.M609509200","article-title":"LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST","volume":"281","author":"Semenov","year":"2006","journal-title":"J Biol Chem"},{"key":"2024020320032289700_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1359\/jbmr.061002","article-title":"Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation","volume":"22","author":"van Bezooijen","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2024020320032289700_bib42","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1074\/jbc.R600015200","article-title":"Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors","volume":"281","author":"Gordon","year":"2006","journal-title":"J Biol Chem"},{"issue":"S1","key":"2024020320032289700_bib43","first-page":"S37","article-title":"Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women","volume":"22","author":"Padhi","year":"2007","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.081206","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/4\/578\/56575945\/5650240403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/4\/578\/56575945\/5650240403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:11:21Z","timestamp":1738703481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/24\/4\/578-588\/7599992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.081206","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1158896.624263","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1158896.620152","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,4,1]]},"published":{"date-parts":[[2009,4,1]]}}}